Skip to main content

Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2



Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears with common symptoms including fever, dry cough, and fatigue, as well as some less common sysmptoms such as loss of taste and smell, diarrhea, skin rashes and discoloration of fingers. COVID-19 patients may also suffer from serious symptoms including shortness of breathing, chest pressure and pain, as well as loss of daily routine habits, pointing out to a sever reduction in the quality of life. COVID-19 has afftected almost all countries, however, the United States contains the highest number of infection (> 1,595,000 cases) and deaths cases (> 95,000 deaths) in the world until May 21, 2020. Finding an influential treatment strategy against COVID-19 can be facilitated through better understanding of the virus pathogenesis and consequently interrupting the biochemical pathways that the virus may play role in human body as the current reservoir of the virus.


In this study, we combined system biology and bioinformatic approaches to define the role of coexpression of angiotensin-converting enzyme 2 (ACE2), neprilysin or membrane metallo-endopeptidase (MME), and carbonic anhydrases (CAs) and their association in the pathogenesis of SARS-CoV-2. The results revealed that ACE2 as the cellular attachment site of SARS-CoV-2, neprilysin, and CAs have a great contribution together in the renin angiotensin system (RAS) and consequently in pathogenesis of SARS-CoV-2 in the vital organs such as respiratory, renal, and blood circulation systems. Any disorder in neprilysin, ACE2, and CAs can lead to increase of CO2 concentration in blood and respiratory acidosis, induction of pulmonary edema and heart and renal failures.


Due to the presence of ACE2-Neprilysin-CA complex in most of vital organs and as a receptor of COVID-19, it is expected that most organs are affected by SARS-CoV-2 such as inflammation and fibrosis of lungs, which may conversely affect their vital functions, temporary or permanently, sometimes leading to death. Therefore, ACE2-Neprilysin-CA complex could be the key factor of pathogenesis of SARS-CoV-2 and may provide us useful information to find better provocative and therapeutic strategies against COVID-19.


Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the worldwide outbreak of coronavirus disease 2019 (COVID-19), the number of infected and death cases have exceeded 4,300,000 and 290,000, respectively until May 21, 2020. Taken together all the observations, world health organization (WHO) declared COVID-19 as a pandemic viral infection based on the prevalence rate and severity of the disease [1, 2] (Table 1).

Table 1 Statistics of worldwide COVID-19 cases until May 21, 2020

The COVID-19 patients suffer from several clinical symtoms including fever, dry cough, fatigue, headache, sore throat, loss of taste and smell, aches and pains, diarrhea, skin rashes and/or discoloration of fingers and toes, shortness of breathing, chest pressure and pain, and loss of speech and movement. Since the outbreak of COVID-19 around the world, many academic groups and pharmaceutical companies have focused on developing therapeutic compounds to provide an effective vaccine against COVID-19. The studies revealed that remdesivir [3], combination of lopinavir and ritonavir (weak recommendation) [4], corticosteroids [5], interferon along with combination of lopinavir and ritonavir [4], and immunoglobulin-therapy through transfusion of immune plasma can be the possible thearapetic options for treatment of COVID-19. For COVID-19 prevention, the studies can focus on the results obtained from SARS-CoV vaccine clinical trials such as application of DNA, viral vector, subunit, viral-like particle, inactivated virus, and live-attenuated virus platforms [6].

To achieve an effective treatment, it is necessary to know more about the mechanism of action and pathogenesis of SARS-CoV-2. Four structural proteins including spike (S), membrane (M), nucleocapsid (N), and envelope (E) antigens are the main constituents of SARS-CoV-2 [7]. S protein is a 150 kDa glycoprotein with a N-terminal signal peptide sequence, which is glycosylated at endoplasmic reticulum (ER) [8]. The most abundant structural protein is M protein (25–30 kDa) comprising three transmembrane domains with crucial roles in the virion formation and stabilizing the complexes during the virion assembly through binding of a small glycosylated N-terminal region of M protein to N protein [9]. N protein (50–60 kDa) binds to RNA through N-terminal domain (NTD) and C-terminal domain (CTD), which is induced by phosphorylation of N protein, genomic packaging signal (GPS), replicase-transcriptase complex (RTC), and transcription regulatory signal (TRS) [10]. E protein (8–12 kDa) is a transmembrane protein with ion channel activity and a major role in assembly and release of virions from the infected cells [11]. Although E protein is not required for replication of the virus, it it plays role in pathogenesis of SARS-CoVs.

At the cellular level, the first viral entry step is the binding of the viral trimeric S protein to the human angiotensin converting enzyme 2 (ACE2) receptor [12]. Moreover, CD147 [13], dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN, CD209) [14] and L-SIGN (CD209L) [15] are other entry receptors for SARS-CoV-2. ACE2 is a glycosylated zinc metallopeptidase and a part of the local renin-angiotensin system (RAS). Based on native function of type I membranous endopeptidases in modification of N-terminal region of proteins, ACE2 contains an extracellular N-terminal active site [16]. This enzyme is expressed in most tissues including kidneys, heart, intestine and lungs, and hydrolyse circulating angiotensisn molecules. ACE2 counteracts the effects of ACE by converting angiotensin I into Ang-(1-7) and reducing the amount of angiotensin II and balancing the ratio of circulating Ang II/ Ang-(1-7) levels [17, 18]. Elevated Ang II production in the pulmonary system triggers local vascular permeability which may result in lung edema [19, 20]. Moreover, Ang II induces pulmonary vasoconstriction in response to hypoxia. Ang-(1-7) has vasodilator, anti-proliferative, and anti-angiogenic properties, while Ang II is a vasoconstrictor, a mitogenic, and an angiogenic factor [21].

In acute respiratory distress syndrome (ARDS), if the RAS does not help in oxygenation, the general lung injury will result in pulmonary failure. Most probably, in ARDS models, ACE2 knockout will result in more severe symptoms, while overexpression might protect the lung from further injury [22].

As mentioned, ACE2 is also exploited by SARS-CoV-2 as the entry receptor. Due to the high expression of ACE2 in the lungs, intestines, respiratory tract, and also enteric system, these organs are the main sites of SARS-CoV-2 infections that are manifested by symptoms like fever, cough, pneumonia, shortness or difficulty of breathing, anorexia, sometimes diarrhea, and abdominal pain [23]. Therefore, it is considered that coronavirus infection can be controlled by blocking ACE2 and preventing the virus from binding to the cells [12]. Despite the mentioned assumption, some animal studies have shown that an increase in Ang-(1-7) has a protective effect against virus-induced lung injury via the vasodilatory effects [22, 24]. It seems that, persistent angiotensin II activity may be partly responsible for organ injury in COVID-19 [19].

Due to insufficient information on the infectious mechanism of the virus, most studies have focused on preventing the first stage of viral infection by reducing ACE2, but ACE2 knock down leads to high activation of local RAS and increased tissue injury, hypertension and renal and cardiovascular complications. Therefore, the evaluation of the efficacy of recently designed vaccines for COVID-19 requires appropriate animal models such as ACE2-transgenic and ACE2-knockout mice [25].

Although, ACE2 is the major producer of Ang-(1-7), there are other enzymes such as neprilysin, prolyl-endo-peptidase (PEP) and prolyl-carboxy-peptidase (PCP) that can produce Ang-(1-7) from Ang I [26, 27]. Among the aforementioned enzymes, high expression levels of neprilysin have been detected in the lung, especially in pulmonary epithelial cells [21]. This zinc-dependent MME is expressed in a wide variety of tissues and in addition to hydrolyzing the Ang I to Ang-(1-7), it is involved in converting several endogenous propeptides into their functional form. According to evidence, neprilysin regulates lung tissue responses to broncho-constriction inducing peptides [21, 28]. Thus, upregulation of neprilysin can be considered as a compensatory mechanism to control the concentration of Ang-(1-7) levels during COVID-19 treatment.

Airway management and hyperbaric oxygen therapy (HBOT) is the main supportive treatments for patients with severe COVID-19 as well as severe pneumonia [29]. Previous studies have revealed that the levels of both angiotensinogen and Ang II receptors increases in hypoxic conditions [30, 31]. Consequently, hypoxic conditions in COVID-19 will increase Ang II concentration through downregulation of ACE2 [32, 33]. Lungs and alveoli as the main parts of lower respiratory system have the main role in the oxygen (O2) exchange with carbon dioxide (CO2) at the molecular level; CA plays a crucial function in this respiratory exchange [34, 35]. CA as another Zn-metalloenzyme catalyzes the hydration of CO2 into carbonic acid and vice versa [36,37,38]. One of the adaptive responses to hypoxia includes the increased expression and functional activation of CA IX [39]. In this study, we applied a system biology approach to explore the association of ACE2, neprilysin, and CA, which may ameliorate COVID-19 symptoms in the lungs alveoli.


Identification of Coexpression of ACE2, Neprilysin, and CA

To identify role of coexpression of ACE2, neprilysin, and CA in COVID-19 pathogenesis, we used COXPRESdb v7 ( [40]. In this database, we applied the CoexViwer algorithm to identify and draw the coexpression of genes, which are linked to activation of neprilysin. This database facilitates the visualization of the multiple gene coexpression information derived from defined animals which were examined with a variety of transcriptomics technologies.

Identification of the Association of Neprilysin and ACE2

To identify the association of neprilysin and ACE2, we employed KEGG (Kyoto Encyclopedia of Genes and Genomes) PATHWAY database [41]. This database represents the information on the reactions, relation networks, and molecular interactions of the molecules.

Identification of Organ Localization of ACE2, Neprilysin, and CA

To identify the organ localization of ACE2, neprilysin, and CA, we used THE HUMAN PROTEIN ATLAS online program ( [42]. This program shows the map of the localization of human proteins in cells, organs, and tissues through application of various system biology, proteomics, and transcriptomics technologies.


Identification of Coexpression of ACE2, Neprilysin, and CA

The coexpression study revealed that ACE2, neprilysin, and CA are codominantly expressed in the local RAS. The analysis showed that at least 22 genes were coexpressed in the local RAS, which can be linked to COVID-19. This association can be a direct or an indirect coexpression effect; so lack of function of a protein as the consequence of COVID-19 infection may induce the expression or activity of another protein in a different pathway (Fig. 1) (Table 2).

Fig. 1

Coexpression of ACE2, neprilysin or MME, and CA in RAS. Red arrows are showing ACE2-Neprilysin-CA association network. The network consist of 22 proteins that two out of them are still not characterized

Table 2 Genes directly connected with neprilysin on the coexpression network

Identification of Association of Neprilysin and ACE2

The KEGG PATHWAY defined that neprilysin and ACE2 have association in the RAS. In this system, via two individual biochemical procedures, neprilysin converts Ang I and Ang-(1-9) to Ang-(1-7). In addition, in the RAS, ACE2 facilitates three individual biochemical procedures including conversion of Ang l to Ang-(1-9) as the substrate of neprilysin, Ang II to Ang-(1-7), and Ang A to alamandine which binds to Mas-related G protein-coupled receptor (MrgprD) to perform the vasodilatory action (Fig. 2).

Fig. 2

Association of neprilysin or MME and ACE2. ACE2 is crucial in conversion of angiotensin I to Ang-(1-9) angiotsnsin II to Ang-(1-7), and angiotensin A (AngA) to alamandine. In addition, neprilysin or MME is essential in conversion of angiotensin I to Ang-(1-7) and Ang-(1-9) to angiotensin Ang-(1-7)

Identification of Organ Localization of ACE2, Neprilysin, and CA

Our analysis based on the data obtained from THE HUMAN PROTEIN ATLAS revealed that neprilysin and ACE2 are highly expressed in the digestive, renal, respiratory, and reproductive systems. The expression pattern of CA in the atlas has shown that this protein is expressed in all human organs. These overlaps in the organ localization of ACE2, neprilysin, and CA demonstrate the possible association of these proteins as a complex in COVID-19 infections through overexpression or down regulation of coding genes expression (Fig. 3).

Fig. 3

Localization of (a) neprilysin or MME, (b) ACE2, and (c) CA VB in the human organs. THE HUMAN PROTEIN ATLAS shows the overlap of bars and association of ACE2, neprilysin, and CA in various organs including digestive, renal, respiratory, and reproductive systems


The successful computational methodologies were employed previously to design viral vaccines against influenza A, hepatitis A, HIV-1, dengue, and West Nile viruses so a new era was considered in the vaccine design studies, which was named reverse vaccinology 2.0 [43,44,45]. This approach was designed and implemented to demonstrate the importance of combination of human immunology, clinical biochemistry, microbial genomics, and system biology to establish novel multidisciplinary approaches in the pathogenesis studies of pathogens and vaccinology researches [45, 46].

The bioinformatics analysis reveals the moderate coexpression of ACE2, neprilysin, and CA genes in the human body. As soon as SARS-CoV-2 is entered into the human oral cavity via direct contact or sneezing and cough droplets of a COVID-19 patient, the virus S protein can be attached to the ACE2, the main host cell receptor of SARS-CoV-2 expressed by epithelial cells of different sites of the oral cavity [47, 48]. Single-cell transcriptome study revealed that the expression rate of ACE2 in the tongue tissue is higher than buccal and gingival tissues [49]. Therefore, primarily SARS-CoV-2 multiplicities in the human mucosa of the oral cavity and consequently a high number of viruses are transmitted to the secondary organ targets expressing ACE2. For this reason, some have claimed drinking water could be a safe way against SARS-CoV-2 which wash the virus into the stomach where acid will inactivate it.

Single-cell sequencing (scRNA-Seq) has shown a high expression rate for ACE2 in type II alveolar (AT2) cells of lung [50], oral cavity epithelial cells [51], upper esophagus [14] and cholangiocytes [52]. A reduction in ACE2 levels due to internalizing by attached SARS-CoV-2 leads to increase in Ang II and consequently vasoconstriction in the lung [53]. Such condition causes respiratory disorders and insufficient air conditioning in alveoli which stimulates lung to upregulate ACE2 expression [54]. According to bioinformatics predictionof the coexpression of ACE2, neprilysin, and CA; an increase in neprilysin and upregulation of CA may attenuate the severity of disease and compensate the alveolar ventilation [55,56,57,58,59]. The elevated Ang II in lung tissue following a decrease in ACE2 by COVID-19 binding may increase the comorbidities, most likely due to inducing local and systemic inflammation. The proinflammatory effects of Ang II are mediated by increased oxidative stress. Elevated serum concentrations of C-reactive protein (CRP) is an indicator of systemic inflammation in such conditions [60].

ACE2 also is expressed in other tissues including proximal tubular cells of kidney [61], colon and ileum of the digestive system [62], urothelial cells of the gallbladder [49], and liver, pancreas and heart myocytes [63], which can justify COVID-19 infection side effects. ACE2 is also expressed in lymphocytes and following infection with the virus, their population decreases and the immune system weakens [13].

Also, different isoenzymes of CA have a high rate of expression in various tissues with critical biochemical functions in the pH homeostasis and alveolar O2-CO2 exchange [64]. After the inhalation, the oxygen is entered to alveoli of lungs with higher pressure than blood capillaries and delivered to hemoglobin in red blood cells (RBCs) [65]. Then, H2CO3 is catalyzed to CO2 and water molecule by CA ll of RBCs. In the acute COVID-19, following the destructive effects of virus on the pulmonary cells, the O2-CO2 exchange rate is impaired, leading to respiratory acidosis and shifting the pH of blood to acidic state and also increasing the concentration of blood CO2 [66]. Subsequently, the kidney proximal tubular cells increase reabsorption of HCO3 leading to acid and ammonium excretion [67]. Then, H+ of the tubular fluid is combined with HCO3 producing H2CO3, which is catalyzed to H2O and CO2 by CAs localized in kidney tissue [68]. Hence, as the consequence of infection of various cells including pulmonary cells of lungs, myocytes of heart, proximal tubular cells of kidney, and other ACE2-expressing cells (which mainly express CAs) with SARS-CoV-2 and reducing the ability of CO2 exhalation, the concentration of blood CO2 is elevated so even the lungs alveoli became unable in O2-CO2 exchange with pulmonary artery and vein through the CA enzymatic reaction [69]. The respiratory acidosis is associated with weakness of the respiratory muscles, arrhythmias, hypotension, myocardial depression, and decreasing in renal blood flow [66]. As the immunological aspect, the respiratory acidosis induces apoptosis and release of proinflammatory cytokines following RAS activation and raising the expression level of angiotensinogen by leukocytes [70]. Finally, the respiratory acidosis can lead to pulmonary edema, severe hypoxia as well as heart and renal failures [66]. Regarding to coexpression analyses results and referring to lack of sufficient information related to human CA VB, we couldn’t find the reason of the coexpression prediction of neprilysin and ACE2 with CA VB, which needs further experiments in future.


Overally, due to high expression rate of ACE2 in the human organs and presence of a potential association with neprilysin in RAS and CAs, SARS-CoV-2 could be considered as an aggressive pathogen to all human organs which express ACE2. Therefore, this pathologic association (ACE2-Neprilysin-CA) complex can present valuable physiologic information to clinicians to innovate more influential treatment protocols against COVID-19.

Availability of Data and Materials

All data analyzed in this study were prepared from online databases, which were included in this article.



Angiotensin-converting enzyme 2


Acute respiratory distress syndrome

HCO3 :


H2CO3 :

Carbonic acid


Carbonic anhydrase


Coronavirus disease 2019

CO2 :

Carbon dioxide


C-reactive protein


Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin




Hyperbaric oxygen therapy


Human immunodeficiency virus


Kyoto Encyclopedia of Genes and Genomes




Membrane metallo-endopeptidase


Mas-related G protein-coupled receptor



O2 :



Renin angiotensin system


Red blood cell




Severe acute respiratory syndrome coronavirus 2


  1. 1.

    Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368:m1036.

    PubMed  Google Scholar 

  2. 2.

    Zolfaghari Emameh R, Nosrati H, Taheri RA. Combination of biodata mining and computational modelling in identification and characterization of ORF1ab polyprotein of SARS-CoV-2 isolated from Oronasopharynx of an Iranian patient. Biol Proced Online. 2020;22:8.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of Remdesivir for patients with severe Covid-19. N Engl J Med. 2020;NEJMoa2007016.

  4. 4.

    Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9.

    PubMed  Google Scholar 

  7. 7.

    McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014;6(8):2991–3018.

    PubMed  PubMed Central  Google Scholar 

  8. 8.

    Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Arndt AL, Larson BJ, Hogue BG. A conserved domain in the coronavirus membrane protein tail is important for virus assembly. J Virol. 2010;84(21):11418–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Zuniga S, Cruz JL, Sola I, Mateos-Gomez PA, Palacio L, Enjuanes L. Coronavirus nucleocapsid protein facilitates template switching and is required for efficient transcription. J Virol. 2010;84(4):2169–75.

    CAS  PubMed  Google Scholar 

  11. 11.

    Verdia-Baguena C, Nieto-Torres JL, Alcaraz A, DeDiego ML, Torres J, Aguilella VM, et al. Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids. Virology. 2012;432(2):485–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Wang X, Xu W, Hu G, Xia S, Sun Z, Liu Z, et al. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020:1–3.

  14. 14.

    Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020;526(1):135–40.

  15. 15.

    Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A. 2004;101(44):15748–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Varland S, Osberg C, Arnesen T. N-terminal modifications of cellular proteins: the enzymes involved, their substrate specificities and biological effects. Proteomics. 2015;15(14):2385–401.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747–803.

    CAS  PubMed  Google Scholar 

  18. 18.

    Gandhi C, Uhal BD. Roles of the angiotensin system in neonatal lung injury and disease. JSM Atheroscler. 2016;1(3):1014.

    PubMed  PubMed Central  Google Scholar 

  19. 19.

    Deng J, Wang DX, Deng W, Li CY, Tong J. The effect of endogenous angiotensin II on alveolar fluid clearance in rats with acute lung injury. Can Respir J. 2012;19(5):311–8.

    PubMed  PubMed Central  Google Scholar 

  20. 20.

    Imai Y, Kuba K, Penninger JM. The renin-angiotensin system in acute respiratory distress syndrome. Drug Discov Today Dis Mech. 2006;3(2):225–9.

    PubMed  PubMed Central  Google Scholar 

  21. 21.

    Gallagher PE, Cook K, Soto-Pantoja D, Menon J, Tallant EA. Angiotensin peptides and lung cancer. Curr Cancer Drug Targets. 2011;11(4):394–404.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol. 2008;93(5):543–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29.

    PubMed  PubMed Central  Google Scholar 

  24. 24.

    Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock (Augusta, Ga). 2016;46(3):239–48.

    CAS  Google Scholar 

  25. 25.

    Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Grobe N, Weir NM, Leiva O, Ong FS, Bernstein KE, Schmaier AH, et al. Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. Am J Phys Cell Phys. 2013;304(10):C945–53.

    CAS  Google Scholar 

  27. 27.

    Domenig O, Manzel A, Grobe N, Konigshausen E, Kaltenecker CC, Kovarik JJ, et al. Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney. Sci Rep. 2016;6:33678.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Wick MJ, Buesing EJ, Wehling CA, Loomis ZL, Cool CD, Zamora MR, et al. Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(3):330–40.

    CAS  PubMed  Google Scholar 

  29. 29.

    Geier MR, Geier DA. Respiratory conditions in coronavirus disease 2019 (COVID-19): important considerations regarding novel treatment strategies to reduce mortality. Med Hypotheses. 2020;140:109760.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Hubloue I, Rondelet B, Kerbaul F, Biarent D, Milani GM, Staroukine M, et al. Endogenous angiotensin II in the regulation of hypoxic pulmonary vasoconstriction in anaesthetized dogs. Crit Care. 2004;8(4):R163–71.

    PubMed  PubMed Central  Google Scholar 

  31. 31.

    Zhao L. al-Tubuly R, Sebkhi a, Owji AA, Nunez DJ, Wilkins MR. angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung. Br J Pharmacol. 1996;119(6):1217–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Mohamed TL, Nguyen HT, Abdul-Hafez A, Dang VX, Dang MT, Gewolb IH, et al. Prior hypoxia prevents downregulation of ACE-2 by hyperoxia in fetal human lung fibroblasts. Exp Lung Res. 2016;42(3):121–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep. 2014;16(3):420.

    PubMed  PubMed Central  Google Scholar 

  34. 34.

    Farhi LE, Plewes JL, Olszowka AJ. Lung carbonate dehydratase (carbonic anhydrase), CO2 stores and CO2 transport. CIBA Found Symp. 1976;38:235–49.

    CAS  Google Scholar 

  35. 35.

    Klocke RA. Catalysis of CO2 reactions by lung carbonic anhydrase. J Appl Physiol Respir Environ Exerc Physiol. 1978;44(6):882–8.

    CAS  PubMed  Google Scholar 

  36. 36.

    Zolfaghari Emameh R, Barker HR, Syrjanen L, Urbanski L, Supuran CT, Parkkila S. Identification and inhibition of carbonic anhydrases from nematodes. J Enzyme Inhib Med Chem. 2016;31(sup4):176–84.

    CAS  PubMed  Google Scholar 

  37. 37.

    Zolfaghari Emameh R, Kuuslahti M, Vullo D, Barker HR, Supuran CT, Parkkila S. Ascaris lumbricoides beta carbonic anhydrase: a potential target enzyme for treatment of ascariasis. Parasit Vectors. 2015;8:479.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Zolfaghari Emameh R, Kuuslahti M, Nosrati H, Lohi H, Parkkila S. Assessment of databases to determine the validity of beta- and gamma-carbonic anhydrase sequences from vertebrates. BMC Genomics. 2020;21(1):352.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019;38(1-2):65–77.

  40. 40.

    Obayashi T, Kagaya Y, Aoki Y, Tadaka S, Kinoshita K. COXPRESdb v7: a gene coexpression database for 11 animal species supported by 23 coexpression platforms for technical evaluation and evolutionary inference. Nucleic Acids Res. 2019;47(D1):D55–62.

    CAS  PubMed  Google Scholar 

  41. 41.

    Du J, Yuan Z, Ma Z, Song J, Xie X, Chen Y. KEGG-PATH: Kyoto encyclopedia of genes and genomes-based pathway analysis using a PATH analysis model. Mol BioSyst. 2014;10(9):2441–7.

    CAS  PubMed  Google Scholar 

  42. 42.

    Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018;27(1):233–44.

    CAS  PubMed  Google Scholar 

  43. 43.

    Khan AM, Hu Y, Miotto O, Thevasagayam NM, Sukumaran R, Abd Raman HS, et al. Analysis of viral diversity for vaccine target discovery. BMC Med Genet. 2017;10(Suppl 4):78.

    Google Scholar 

  44. 44.

    Hasan M, Ghosh PP, Azim KF, Mukta S, Abir RA, Nahar J, et al. Reverse vaccinology approach to design a novel multi-epitope subunit vaccine against avian influenza a (H7N9) virus. Microb Pathog. 2019;130:19–37.

    CAS  PubMed  Google Scholar 

  45. 45.

    Rappuoli R, Bottomley MJ, D'Oro U, Finco O, De Gregorio E. Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. J Exp Med. 2016;213(4):469–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Zolfaghari Emameh R, Kuuslahti M, Nareaho A, Sukura A, Parkkila S. Innovative molecular diagnosis of Trichinella species based on beta-carbonic anhydrase genomic sequence. Microb Biotechnol. 2016;9(2):172–9.

    CAS  PubMed  Google Scholar 

  47. 47.

    Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215.

    CAS  PubMed  Google Scholar 

  49. 49.

    Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Uhal BD, Dang M, Dang V, Llatos R, Cano E, Abdul-Hafez A, et al. Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis. Eur Respir J. 2013;42(1):198–210.

    CAS  PubMed  Google Scholar 

  51. 51.

    de Carvalho Fraga CA, Farias LC, Jones KM. Batista de Paula AM, Guimaraes ALS. Angiotensin-converting enzymes (ACE and ACE2) as potential targets for malignant epithelial neoplasia: review and bioinformatics analyses focused in Oral squamous cell carcinoma. Protein Pept Lett. 2017;24(9):784–92.

    PubMed  Google Scholar 

  52. 52.

    Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428.

    PubMed  PubMed Central  Google Scholar 

  53. 53.

    South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16(6):305.

    CAS  PubMed  Google Scholar 

  54. 54.

    Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun. 2020;1:102463.

    Google Scholar 

  55. 55.

    Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-angiotensin system in kidney physiology. Compr Physiol. 2014;4(3):1201–28.

    PubMed  PubMed Central  Google Scholar 

  56. 56.

    Ahmad S, Varagic J, Groban L, Dell’Italia LJ, Nagata S, Kon ND, et al. Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep. 2014;16(5):429.

    PubMed  PubMed Central  Google Scholar 

  57. 57.

    Park S. Ideal target blood pressure in hypertension. Korean Circ J. 2019;49(11):1002–9.

    PubMed  PubMed Central  Google Scholar 

  58. 58.

    Simoni J, Simoni G, Moeller JF, Tsikouris JP, Wesson DE. Evaluation of angiotensin converting enzyme (ACE)-like activity of acellular hemoglobin. Artif Cells Blood Substit Immobil Biotechnol. 2007;35(2):191–210.

    CAS  PubMed  Google Scholar 

  59. 59.

    Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/angiotensin 1-7 Axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118(8):1313–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Bansal T, Pandey A. D D, Asthana AK. C-reactive protein (CRP) and its association with periodontal disease: a brief review. J Clin Diagn Res. 2014;8(7):ZE21–4.

    PubMed  PubMed Central  Google Scholar 

  61. 61.

    Soler MJ, Wysocki J, Batlle D. ACE2 alterations in kidney disease. Nephrol Dial Transplant. 2013;28(11):2687–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. 62.

    Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J, et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids. 2015;47(4):693–705.

    CAS  PubMed  Google Scholar 

  63. 63.

    Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008;295(6):H2373–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Everaert N, Willemsen H, Hulikova A, Brown H, Decuypere E, Swietach P, et al. The importance of carbonic anhydrase II in red blood cells during exposure of chicken embryos to CO2. Respir Physiol Neurobiol. 2010;172(3):154–61.

    CAS  PubMed  Google Scholar 

  65. 65.

    Carlson BE, Anderson JC, Raymond GM, Dash RK, Bassingthwaighte JB. Modeling oxygen and carbon dioxide transport and exchange using a closed loop circulatory system. Adv Exp Med Biol. 2008;614:353–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. 66.

    Bruno CM, Valenti M. Acid-base disorders in patients with chronic obstructive pulmonary disease: a pathophysiological review. J Biomed Biotechnol. 2012;2012:915150.

    PubMed  PubMed Central  Google Scholar 

  67. 67.

    DuBose TD Jr. Carbonic anhydrase-dependent bicarbonate transport in the kidney. Ann N Y Acad Sci. 1984;429:528–37.

    CAS  PubMed  Google Scholar 

  68. 68.

    Frommer JP, Wesson DE, Laski ME, Kurtzman NA. Generation of reabsorptive bicarbonate concentration gradients between vasa recta and papillary tubular fluid after inhibition of carbonic anhydrase in the rat kidney. Ann N Y Acad Sci. 1984;429:541–3.

    CAS  PubMed  Google Scholar 

  69. 69.

    Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.

    PubMed  PubMed Central  Google Scholar 

  70. 70.

    Liao Z, Chakrabarty A, Mu Y, Bhattacherjee A, Goestch M, Leclair CM, et al. A local inflammatory renin-angiotensin system drives sensory axon sprouting in provoked Vestibulodynia. J Pain. 2017;18(5):511–25.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references


We thank the Deputy of Research and COVID-19 National Committee at the National Institute of Genetic Engineering and Biotechnology (NIGEB) of the Islamic Republic of Iran for preparing the condition to perform this study. No funding organizations had any role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; nor in the decision to publish the results.


To perform this study, RZE received a research grant support from the National Institute of Genetic Engineering and Biotechnology (NIGEB) of the Islamic Republic of Iran.

Author information




All authors participated in the design of the study. RZE designed and carried out the search and data mining related to the coexpression of ACE2-Neprilysin-CA complex as well as databases for this study. RZE performed the system biology and bioinformatic studies. RF participated in the immunological and EB participated in the biochemical studies and further revision of the manuscript. All authors participated in writing further versions and read and approved the final manuscript.

Corresponding author

Correspondence to Reza Zolfaghari Emameh.

Ethics declarations

Ethics Approval and Consent to Participate

Not applicable.

Consent for Publication

All authors have read and approved the final version of the manuscript.

Competing Interests

The authors declare that they have no conflict of interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zolfaghari Emameh, R., Falak, R. & Bahreini, E. Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2. Biol Proced Online 22, 11 (2020).

Download citation


  • SARS-CoV-2
  • COVID-19
  • Angiotensin-converting enzyme 2 (ACE2)
  • Neprilysin
  • Carbonic anhydrases (CAs)
  • Renin angiotensin system (RAS)
  • Acute respiratory syndrome
  • Respiratory acidosis